ATG13

Across TCGA pan-cancer cohorts, ATG13 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated ATG13 data layer compared with 2 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ATG13 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG13 expression acts as an unfavorable survival marker, although some lineages such as LGG and UCEC show a favorable association.

LIHC, ACC, and LGG are the cancer types where ATG13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.469	0.612	<.001	98	view →
ACC	DFS	Median	All	0.228	0.703	<.001	68	view →
LGG	DFS	Median	All	0.807	0.669	<.001	38	view →
LUSC	DFS	Median	III,IV	0.523	0.916	.009	32	view →
COAD	DFS	Tertile	All	0.618	0.740	.012	24	view →
UCEC	OS	Tertile	IV	0.770	0.337	.002	22	view →
BRCA	DFS	Quartile	III,IV	0.848	0.676	.016	21	view →
HNSC	OS	Median	All	0.616	0.799	.004	17	view →
KICH	DFS	Tertile	III,IV	0.303	1.000	.022	17	view →
PAAD	OS	Tertile	II,III,IV	0.624	0.421	.005	16	view →
READ	OS	Median	All	0.937	0.320	.006	10	view →
LUAD	OS	Tertile	All	0.268	0.427	.027	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

ATG13–LIHC (DFS)

Open the LIHC breakdown →